Peer-reviewed veterinary case report
Angiopoietin-2 blood levels in dogs with splenic tumors
By Wongsuttawas, Supissara et al.·Published in Acta veterinaria Hungarica·2021·Faculty of Veterinary Science·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: Serum angiopoietin-2 levels in dogs with splenic haemangiosarcoma, haemangioma, and splenitis.
- Species:
- dog
Plain-English summary
A group of dogs with abnormal splenic masses, including some with splenic tumors called hemangiosarcoma (HSA) and hemangioma (HA), were studied to see if a blood marker called angiopoietin-2 (Ang-2) could help differentiate between these conditions. The results showed that Ang-2 levels were higher in dogs with splenic HA compared to those with HSA, and also higher in dogs with splenitis (inflammation of the spleen) than in healthy dogs. However, Ang-2 levels did not correlate with the severity of the disease or survival time in dogs with HSA. This suggests that measuring Ang-2 could help identify certain splenic issues in dogs, but it may not predict outcomes for those with HSA.
People also search for: dog splenic tumor symptoms · hemangiosarcoma treatment in dogs · elevated angiopoietin-2 in dogs
Abstract
Haemangioma (HA) and haemangiosarcoma (HSA) are among the most common splenic neoplasms in dogs. The survival time in splenic HSA is short, probably due to the lack of proper biological markers allowing early detection. We investigated the serum angiopoietin-2 (Ang-2) concentrations in 9 healthy dogs and 40 dogs with abnormal splenic masses. The Ang-2 concentration differences were further compared in healthy dogs, dogs with splenitis, splenic HA and HSA. The results showed that the Ang-2 level in healthy dogs was significantly lower than in the splenitis and splenic HA cases. Moreover, the Ang-2 level was significantly higher in splenic HA than in splenic HSA. Conversely, no significant differences in Ang-2 level were recorded between healthy and splenic HSA dogs, and between splenitis and splenic neoplasms (HA and HSA). No significant correlations were observed between the Ang-2 level and (i) the clinical stage, (ii) histological growth pattern, and (iii) median survival time of splenic HSA dogs. In conclusion, serum Ang-2 concentration is a potentially useful biological marker for the discrimination of dogs with splenitis and splenic HA, as well as for the differentiation of splenic HA from its malignant form, HSA.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/33964126/